MilliporeSigma, Merck KGaA’s U.S. and Canada Life Science business, announced a $76 million expansion of its ADC manufacturing capabilities and capacity. The company is expanding the capacity at its Bioconjugation Center of Excellence facility in St. Louis. This investment triples existing capacity and enhances the company’s contract development and manufacturing organization (CDMO) offering. MilliporeSigma said…
MilliporeSigma opens $317M biosafety plant in Maryland
MilliporeSigma, the U.S. and Canadian Life Science unit of Merck KGaA (Darmstadt, Germany) announced today that it opened a new $317 million (€290) biosafety testing facility in Rockville, Maryland. The 23,000-square-meter facility houses biosafety testing, analytical development and cell banking manufacturing services. It consolidates labs currently spread across four buildings into one single facility. MilliporeSigma…
Merck KGaA completes €180M Schnelldorf distribution center expansion
Merck KGaA, Darmstadt, Germany announced that it opened its newly expanded Life Science distribution center in Schnelldorf. The company invested €180 million and added 25,000 square meters in space to the site, nearly doubling its size. It now features a manual down filling operation and additional space for the distribution of products to laboratories and…
MilliporeSigma to invest €300M in new bioprocessing plant in South Korea
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA (Darmstadt, Germany), announced a €300 million in South Korea. The investment goes toward a new bioprocessing production center in Daejon, South Korea. It marks the largest investment by the company’s life science business sector in Asia-Pacific to date. The company expects the investment to…
Roche to donate essential medicines to Ukraine
Roche (SIX:RO, ROG; OTCQX:RHHBY) announced that it would ship 150,000 packages of the antibiotic Rocephin to Ukraine, among other medical supplies, including diagnostics. Rocephin is a broad-spectrum cephalosporin antibiotic. The World Health Organization cites it as an essential medicine. Basel, Switzerland–headquartered Roche noted in a statement that it is working with various international and local…
Merck KGaA, Darmstadt, Germany acquires Exelead to bolster mRNA offerings
Merck KGaA, Darmstadt, Germany has announced that it has signed a definitive agreement to purchase Exelead (Indianapolis), a biopharma contract development and manufacturing organization (CDMO). Not to be confused with the similarly named Merck & Co., the German company will pay roughly $780 million in the acquisition. Exelead specializes in creating lipid nanoparticle and pegylated…